Novel immunoassays for detection of CUZD1 autoantibodies in serum of patients with inflammatory bowel diseases
Author
Farkona S., Soosaipillai A., Filippou P., Liaskos C., Bogdanos D.P., Diamandis E.P., Blasutig I.M.Date
2017Language
en
Keyword
Abstract
Pancreatic autoantibodies (PABs) are detected in patients with inflammatory bowel disease (IBD). Their prevalence is higher in Crohn's disease (CrD) than in ulcerative colitis (UC). Glycoprotein 2 (GP2) and, more recently, CUB and zona pellucida-like domain-containing protein 1 (CUZD1) have been identified as target autoantigens of PAB. The clinical utility of CUZD1 autoantibodies has only recently been assessed by indirect immunofluorescence (IIF) assays. In this study, we developed and validated novel immunoassays for the detection of CUZD1 autoantibodies. Recombinant CUZD1 protein was utilized as a solid-phase antigen for the development of two immunoassays for the detection of IgG and IgA CUZD1 autoantibodies. Serum samples from 100 patients with CrD, 100 patients with UC, 129 patients assessed for various autoimmune diseases (vADs) and 50 control individuals were analyzed. Two immunofluorometric assays for the detection of IgG and IgA CUZD1-specific antibodies were developed. CUZD1 autoantibodies were detected in 12.5% (25/200) IBD patients, including 16% of patients with CrD and in 9% of patients with UC (CrD vs. UC, p<0.05), compared with 3.1% (4/129) patients suspected of having vADs (CrD vs. ADs, p<0.05; UC vs. ADs, p=0.08). CUZD1 autoantibody positivity was not found to be related to disease location, age of disease onset or disease phenotype. This is the first study to describe novel IgA and IgG CUZD1 autoantibody enzyme-linked immunosorbent assay. These immunoassays agree well with standard IIF techniques and can be utilized in multicenter studies to investigate the diagnostic and clinical utility of CUZD1 autoantibodies. © 2017 Walter de Gruyter GmbH, Berlin/Boston.
Collections
Related items
Showing items related by title, author, creator and subject.
-
Diagnostic and clinical significance of Crohn's disease-specific pancreatic anti-GP2 and anti-CUZD1 antibodies
Pavlidis P., Komorowski L., Teegen B., Liaskos C., Koutsoumpas A.L., Smyk D.S., Perricone C., Mytilinaiou M.G., Stocker W., Forbes A., Bogdanos D.P. (2016)Background: Pancreatic autoantibodies (PAB) targeting GP2 and CUZD1 are Crohn's disease (CrD)-markers. The clinical significance of anti-GP2 antibodies has been assessed, but that of anti-CUZD1 remains elusive. The aim of ... -
(2-Heremans-schmid glycoprotein (fetuin A) downregulation and its utility in inflammatory bowel disease
Manolakis A.C., Christodoulidis G., Kapsoritakis A.N., Georgoulias P., Tiaka E.K., Oikonomou K., Valotassiou V.J., Potamianos S.P. (2017)AIM: To investigate the impact of inflammatory bowel disease (IBD) on α2-Heremans-Schmid Glycoprotein (AHSG/fetuin A) and potential associations with disease and patient characteristics. METHODS: AHSG serum levels were ... -
PBC Screen: An IgG/IgA dual isotype ELISA detecting multiple mitochondrial and nuclear autoantibodies specific for primary biliary cirrhosis
Liu, H.; Norman, G. L.; Shums, Z.; Worman, H. J.; Krawitt, E. L.; Bizzaro, N.; Vergani, D.; Bogdanos, D. P.; Dalekos, G. N.; Milkiewicz, P.; Czaja, A. J.; Heathcote, E. J.; Hirschfield, G. M.; Tan, E. M.; Miyachi, K.; Bignotto, M.; Battezzati, P. M.; Lleo, A.; Leung, P. S.; Podda, M.; Gershwin, M. E.; Invernizzi, P. (2010)A dual isotype (IgG, IgA) enzyme-linked immunosorbent assay (ELISA) designed to provide enhanced detection of primary biliary cirrhosis (PBC)-specific autoantibodies against both major mitochondrial and nuclear antigens ...